Genmab As Stock Current Valuation
| GMAB Stock | DKK 1,937 6.00 0.31% |
Valuation analysis of Genmab AS helps investors to measure Genmab AS's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Genmab AS's price fluctuation is very steady at this time. Calculation of the real value of Genmab AS is based on 3 months time horizon. Increasing Genmab AS's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Genmab AS is useful when determining the fair value of the Genmab stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Genmab AS. Since Genmab AS is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Genmab Stock. However, Genmab AS's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1937.0 | Real 1646.45 | Hype 1937.0 | Naive 1865.49 |
The real value of Genmab Stock, also known as its intrinsic value, is the underlying worth of Genmab AS Company, which is reflected in its stock price. It is based on Genmab AS's financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Genmab AS's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Genmab AS's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Genmab AS helps investors to forecast how Genmab stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Genmab AS more accurately as focusing exclusively on Genmab AS's fundamentals will not take into account other important factors: Genmab AS Company Current Valuation Analysis
Genmab AS's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Genmab AS Current Valuation | 186.33 B |
Most of Genmab AS's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Genmab AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Genmab AS has a Current Valuation of 186.33 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Biotechnology industry. The current valuation for all Denmark stocks is significantly lower than that of the firm.
Genmab Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Genmab AS's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Genmab AS could also be used in its relative valuation, which is a method of valuing Genmab AS by comparing valuation metrics of similar companies.Genmab AS is currently under evaluation in current valuation category among related companies.
Genmab Fundamentals
| Return On Equity | 0.24 | |||
| Return On Asset | 0.1 | |||
| Profit Margin | 0.47 % | |||
| Operating Margin | 0.38 % | |||
| Current Valuation | 186.33 B | |||
| Shares Outstanding | 65.96 M | |||
| Shares Owned By Institutions | 49.90 % | |||
| Price To Earning | 34.78 X | |||
| Price To Book | 7.86 X | |||
| Price To Sales | 17.00 X | |||
| Revenue | 8.48 B | |||
| Gross Profit | 8.48 B | |||
| EBITDA | 4.24 B | |||
| Net Income | 3.01 B | |||
| Cash And Equivalents | 18.08 B | |||
| Cash Per Share | 276.57 X | |||
| Total Debt | 378 M | |||
| Debt To Equity | 0.02 % | |||
| Current Ratio | 15.42 X | |||
| Book Value Per Share | 408.67 X | |||
| Cash Flow From Operations | 2.23 B | |||
| Earnings Per Share | 83.21 X | |||
| Price To Earnings To Growth | 1.19 X | |||
| Target Price | 3239.73 | |||
| Number Of Employees | 1.56 K | |||
| Beta | 0.67 | |||
| Market Capitalization | 185.21 B | |||
| Total Asset | 24.63 B | |||
| Net Asset | 24.63 B |
About Genmab AS Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Genmab AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Genmab AS using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Genmab AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genmab AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Genmab Stock, please use our How to Invest in Genmab AS guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Complementary Tools for Genmab Stock analysis
When running Genmab AS's price analysis, check to measure Genmab AS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genmab AS is operating at the current time. Most of Genmab AS's value examination focuses on studying past and present price action to predict the probability of Genmab AS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genmab AS's price. Additionally, you may evaluate how the addition of Genmab AS to your portfolios can decrease your overall portfolio volatility.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Stocks Directory Find actively traded stocks across global markets | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |